Milan G Chheda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1572847/publications.pdf

Version: 2024-02-01

25 papers 1,116 citations

933447 10 h-index 18 g-index

28 all docs 28 docs citations

times ranked

28

2258 citing authors

#	Article	IF	CITATIONS
1	A randomized feasibility study evaluating temozolomide circadian medicine in patients with glioma. Neuro-Oncology Practice, 2022, 9, 193-200.	1.6	11
2	Prospective biomarker study in newly diagnosed glioblastoma: Cyto-C clinical trial. Neuro-Oncology Advances, 2022, 4, vdab186.	0.7	1
3	The state of neuro-oncology during the COVID-19 pandemic: a worldwide assessment. Neuro-Oncology Advances, 2021, 3, vdab035.	0.7	3
4	Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell, 2021, 39, 509-528.e20.	16.8	327
5	Re-evaluating Biopsy for Recurrent Glioblastoma: A Position Statement by the Christopher Davidson Forum Investigators. Neurosurgery, 2021, 89, 129-132.	1.1	5
6	Defining phenotypic and functional heterogeneity of glioblastoma stem cells by mass cytometry. JCI Insight, 2021, 6, .	5.0	10
7	Zika virus oncolytic activity requires CD8+ T cells and is boosted by immune checkpoint blockade. JCI Insight, 2021, 6, .	5.0	46
8	Salvage therapies for radiation-relapsed isocitrate dehydrogenase-mutant astrocytoma and $1p/19q$ codeleted oligodendroglioma. Neuro-Oncology Advances, 2021, 3, vdab081.	0.7	1
9	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro-Oncology, 2020, 22, 470-479.	1.2	49
10	A Fyn romance: tumor cell Fyn kinase suppresses the immune microenvironment. Neuro-Oncology, 2020, 22, 746-747.	1.2	1
11	EXTH-14. A NOVEL LONG-ACTING INTERLEUKIN-7 AGONIST, NT-17, INCREASES CYTOTOXIC CD8 CELLS AND ENHANCES SURVIVAL IN MOUSE GLIOMA MODELS. Neuro-Oncology, 2020, 22, ii89-ii89.	1.2	O
12	565â€A novel long-acting interleukin-7 agonist, NT-17, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models. , 2020, , .		1
13	STEM-13. FUNCTIONAL CHARACTERIZATION OF THE ZFHX4-CHD4 INTERACTION IN GLIOBLASTOMA CANCER STEM CELLS. Neuro-Oncology, 2020, 22, ii199-ii199.	1.2	0
14	IMMU-43. ZIKA VIRUS TO TREAT GLIOMA: TURNING COLD TUMORS HOT. Neuro-Oncology, 2020, 22, ii114-ii114.	1.2	0
15	STEM-17. NOT ALL GBM STEM CELLS ARE EQUAL: IMPLICATIONS FOR RESEARCH AND THERAPY. Neuro-Oncology, 2020, 22, ii199-ii200.	1.2	0
16	COVD-31. THE STATE OF NEURO-ONCOLOGY DURING THE COVID-19 PANDEMIC: A WORLDWIDE ASSESSMENT. Neuro-Oncology, 2020, 22, ii27-ii27.	1.2	0
17	CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma. Scientific Reports, 2019, 9, 4444.	3.3	33
18	The impact of systemic precision medicine and immunotherapy treatments on brain metastases. Oncotarget, 2019, 10, 6739-6753.	1.8	13

#	Article	IF	CITATION:
19	Consumption of NADPH for 2-HG Synthesis Increases Pentose Phosphate Pathway Flux and Sensitizes Cells to Oxidative Stress. Cell Reports, 2018, 22, 512-522.	6.4	74
20	Understanding the Impact of IDH2 Mutations on the Redox Balance of Cancer Cells. FASEB Journal, 2018, 32, 811.13.	0.5	0
21	Using Epigenetic Reprogramming to Treat Pediatric Brain Cancer. Cancer Cell, 2017, 31, 609-611.	16.8	5
22	Zika virus has oncolytic activity against glioblastoma stem cells. Journal of Experimental Medicine, 2017, 214, 2843-2857.	8.5	179
23	Impact of concurrent chemotherapy with radiation therapy for elderly patients with newly diagnosed glioblastoma: a review of the National Cancer Data Base. Journal of Neuro-Oncology, 2017, 131, 593-601.	2.9	27
24	ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State. Cell Reports, 2014, 6, 313-324.	6.4	106
25	PLAGL2 Regulates Wnt Signaling to Impede Differentiation in Neural Stem Cells and Gliomas. Cancer Cell, 2010, 17, 497-509.	16.8	224